Welcome to our dedicated page for Pulse Biosciences SEC filings (Ticker: PLSE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pulse Biosciences, Inc. (Nasdaq: PLSE) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered summaries to help interpret complex documents. As a medical device developer focused on bioelectric medicine and nanosecond pulsed field ablation (nsPFA) technology, Pulse Biosciences uses its SEC filings to describe clinical programs, financial performance, governance matters and key milestones for its nPulse platforms.
Investors can review Form 10-K and 10-Q filings for detailed discussions of the company’s business, risk factors, research and development spending and revenue from nPulse capital equipment and Vybrance disposables. Form 8-K current reports highlight material events such as FDA Investigational Device Exemption (IDE) approvals for the NANOCLAMP AF and NANOPULSE-AF atrial fibrillation studies, publication of first-in-human thyroid data, initiation of clinical trials, and quarterly business updates and financial results.
The company’s DEF 14A definitive proxy statement outlines corporate governance, board structure, equity incentive plans and executive compensation policies, providing insight into how management and directors are incentivized as Pulse Biosciences advances its nsPFA technology. Other exhibits and schedules within these filings can include information on stockholder votes, amendments to equity plans and non-GAAP financial measures used by management.
On Stock Titan, each PLSE filing is supplemented with AI-generated explanations that clarify technical language, summarize key sections and point out items such as clinical trial descriptions, regulatory designations and capital structure changes. Users can also monitor Form 4 insider transaction filings when available to see how officers and directors transact in company stock. Together, these tools allow investors, analysts and clinicians to quickly understand the implications of Pulse Biosciences’ SEC filings without reading every line of each document.
Pulse Biosciences, Inc. reported early commercial revenue and higher operating losses as it advances its nPulse nanosecond PFA platform. Fourth quarter 2025 revenue was $264 thousand, up from $86 thousand in the prior quarter, and full-year 2025 revenue reached $350 thousand.
GAAP costs and expenses for 2025 were $77.3 million, up from $56.3 million, driving a GAAP net loss of $72.8 million versus $53.6 million a year earlier. Non-GAAP net loss rose to $50.8 million from $36.9 million. Cash and cash equivalents were $80.7 million as of December 31, 2025, down from $118.0 million a year earlier.
The company highlighted strong feasibility data in atrial fibrillation, with 100% procedural success at six months and 96% at one year in evaluable patients treated with the nPulse Cardiac Catheter System. It received FDA approval to commence a pivotal IDE study in paroxysmal AF, is running the NANOCLAMP AF surgical IDE pivotal study, and is expanding soft tissue ablation efforts, including a collaboration with MD Anderson for thyroid tumors.
Pulse Biosciences, Inc. filed a shelf registration to offer up to $200,000,000 of securities. The registration permits the sale, from time to time, of common stock, preferred stock, debt securities, depositary shares, warrants, subscription rights, purchase contracts and units under a prospectus dated February 19, 2026.
The prospectus states offerings will be made by prospectus supplement describing amounts, prices and terms, and notes the company’s common stock trades on the Nasdaq Capital Market under the symbol PLSE; the last reported sale price on February 18, 2026 was $25.46.
Pulse Biosciences, Inc. entered into a sales agreement with TD Securities (USA) LLC to sell up to $59,976,196 of its common stock in an at-the-market offering under a shelf registration.
The supplement states the offering may be made from time to time through TD Cowen, that TD Cowen will act as sales agent for up to $59,976,196, and that compensation to TD Cowen may be up to 3% of gross proceeds. Shares outstanding used for illustrative dilution are 67,839,689 as of December 31, 2025.
Pulse Biosciences, Inc. entered into a new equity distribution agreement with TD Securities (USA) LLC, allowing the company to sell, from time to time, shares of common stock with an aggregate offering price of up to $59,976,196 in at-the-market transactions. TD Cowen will act as sales agent and receive a commission of up to 3.0% of the gross sales price of shares sold, plus specified expense reimbursements. The shares will be issued under existing effective shelf registration statements and a prospectus supplement filed on February 19, 2026. On February 18, 2026, the company terminated its prior at-the-market program, under which the same aggregate amount of common stock remained unsold.
Pulse Biosciences is a pre-commercial medical device company developing Nano-pulse Stimulation (nsPFA) ablation technology across cardiology and soft tissue applications. It has FDA 510(k) clearance for its Vybrance Percutaneous Electrode System for soft tissue ablation and has completed more than 300 patient procedures.
The company is advancing a cardiac surgical clamp and endocardial catheter for atrial fibrillation, supported by Breakthrough Device Designation and approved Investigational Device Exemptions for pivotal studies in the United States and Europe. Pulse holds over 250 issued patents but has no significant revenue, continues to incur losses, and warns that additional capital and favorable reimbursement are critical to its plans.
PULSE BIOSCIENCES, INC. Chief Commercial Officer Kevin Patrick Danahy exercised stock options and sold shares in mid-February. He exercised options covering 60,000 shares of Common Stock at a strike price of $1.53 per share and sold 60,000 shares in open-market transactions at weighted average prices of $23.37, $23.53, and $23.63 per share.
These trades were executed under a Rule 10b5-1 trading plan adopted on May 14, 2025. Following the transactions, Danahy directly holds 43,298 shares of Common Stock and 305,000 stock options from a 2022 grant for up to 450,000 shares that vests over four years.
A shareholder of PLSE has filed a Form 144 notice indicating an intention to sell 50,000 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,262,500. The shares relate to an exercise of stock options for 50,000 common shares paid in cash on 02/12/2026.
The filing notes that 67,767,578 shares of the issuer’s common stock were outstanding and that the planned sale is expected around 02/12/2026 on the NASDAQ. It also discloses prior Rule 10b5-1 sales for Kevin Danahy over the past three months, including 20,000-share transactions on 02/09/2026, 02/10/2026, and 02/11/2026 with stated gross proceeds of $429,070.00, $470,498.00, and $503,924.00.
Pulse Biosciences Chief Commercial Officer Kevin Patrick Danahy reported a series of option exercises and share sales in Pulse Biosciences, Inc. common stock. On February 9, 10, and 11, 2026, he exercised 20,000 stock options at an exercise price of $1.53 per share each day, converting them into 20,000 common shares per day.
On each of those same dates, he then sold 20,000 common shares in open-market transactions at weighted average prices of $21.45, $23.52, and $25.20 per share, respectively, leaving 43,298 common shares held directly after each day’s sale. These trades were carried out under a Rule 10b5‑1 trading plan adopted on May 14, 2025.
Following the reported transactions, Danahy directly holds 365,000 stock options with an exercise price of $1.53 per share, originally granted on September 23, 2022 for up to 450,000 shares, with 25% vesting on each anniversary of the grant date.
A shareholder of Pulse Biosciences (PLSE) has filed a notice to sell 75,000 shares of common stock under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an aggregate market value of $1,556,250 based on the filer’s stated price.
The securities were acquired on 02/09/2026 through a cash exercise of stock options from the issuer, with payment also made on that date. The form indicates no other sales of the issuer’s securities by this person in the past three months.
Pulse Biosciences director Maria Sainz received new stock options in early 2026. On January 8, 2026, she was granted options to buy 50,000 shares of common stock at $14.72 per share. On February 5, 2026, she received options for 3,104 shares at $13.69 per share.
One-third of the 50,000-share grant will vest on the one-year anniversary of the grant, with the rest vesting monthly over the following two years, assuming continued service. The 3,104-share grant will vest in equal installments on March 5, 2026 and June 5, 2026, also conditioned on continued service.